Louise Frederika Kooij Sells 40,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 40,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $735,460.60. This trade represents a 62.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Stock Up 3.8%

Shares of NAMS traded up $1.21 on Wednesday, hitting $32.60. The company’s stock had a trading volume of 1,235,979 shares, compared to its average volume of 1,027,622. The firm’s fifty day moving average price is $32.94 and its 200-day moving average price is $33.19. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $17.67 and a fifty-two week high of $42.21. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of -18.22 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million for the quarter. As a group, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its position in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of NewAmsterdam Pharma by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after acquiring an additional 437 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of NewAmsterdam Pharma by 5.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its position in shares of NewAmsterdam Pharma by 6.7% in the first quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock valued at $469,000 after acquiring an additional 925 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

NAMS has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Truist Financial initiated coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.